Navigation Links
Reportlinker Adds U.S. Retinal Therapeutics Market
Date:6/22/2011

NEW YORK, June 22, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

U.S. Retinal Therapeutics Market

http://www.reportlinker.com/p0559274/US-Retinal-Therapeutics-Market.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment

This research service provides an indepth analysis of factors affecting the growth of the U.S. retinal therapeutics market over the period 2006-2016. Included are disease and treatment overviews, product analyses, patient forecasts, product revenue forecasts, and market share analyses. In this research service, the market is segmented by retinal disease: age-related macular degeneration (AMD), diabetic retinopathy (DR)/diabetic macular edema (DME), and both branch and central retinal vein occlusion (BRVO/CRVO). Major market challenges, drivers, and restraints are identified and discussed. Additionally, a pipeline of compounds making their way through clinical trials is presented in the "Product Pipeline" section of this research service.

Table of Contents

C h a p t e r 1

Executive Summary

U.S. Retinal Therapeutics Market 1-1

Introduction 1-1

C h a p t e r 5

Appendix

Decision Support Databases 1-1

Total Population 1-1

Population Aged 15 to 24 Years 1-3

Population Aged 25 to 34 Years 1-5

Population Aged 35 to 44 Years 1-7

Population Aged 45 to 54 Years 1-9

Population Aged 55 to 64 Years 1-11

Population Above 45 Years 1-13

Population Above 65 Years 1-15

AMD Prevalence 1-17

AMD Incidence 1-20

Diabetes Prevalence 1-22

Diabetes Incidence 1-24

C h a p t e r 4

Market Analysis

Market Outlook and Revenue Forecasts 1-1

Age-related Macular Degeneration 1-1

WET AMD 1-1

Diabetic Retinopathy and Diabetic Macular Edema 1-18

ANTI-VEGFs 1-19

CORTICOSTEROIDS 1-24

OTHER LATE-STAGE CANDIDATES 1-33

Retinal Vein Occlusion 1-34

CORTICOSTEROIDS 1-34

ANTI-VEGFs 1-35

VEGF Trap-Eye 1-36

Competitive Overview 1-37

Competitive Structure 1-37

C h a p t e r 3

Treatment Overview and Product Pipeline

Treatment Overview 1-1

Age-Related Macular Degeneration 1-1

Product Analysis and Treatment Practices for AMD 1-1

Visudyne (Verteporfin) 1-1

Macugen (Pegaptanib) 1-2

Lucentis (Ranibizumab) 1-2

Avastin (Bevacizumab) 1-3

Other Treatment Practices 1-3

Diabetic Retinopathy and Diabetic Macular Edema 1-4

Current Treatments and Practices for Diabetic Retinopathy 1-4

Current Treatments and Practices for Diabetic Macular Edema 1-4

Retinal Vein Occlusion 1-5

Product Pipeline 1-6

Age-Related Macular Degeneration 1-6

Diabetic Retinopathy and Diabetic Macular Edema 1-8

Retinal Vein Occlusion 1-9

C h a p t e r 2

Market Introduction

Research Scope and Methodology 1-1

Scope and Segmentation 1-1

Research Methodology 1-2

Market Overview 1-2

Introduction 1-2

Disease Overviews 1-3

Age-Related Macular Degeneration 1-3

Diabetic Retinopathy and Diabetic Macular Edema 1-4

Retinal Vein Occlusion 1-5

Clinical Need and Burden of Disease 1-5

Age-related Macular Degeneration 1-5

Wet and Dry AMD Prevalence 1-5

Wet AMD Treated Patient Forecast 1-8

Diabetic Retinopathy and Diabetic Macular Edema 1-10

Diabetic Retinopathy 1-10

Diabetic Macular Edema 1-12

Retinal Vein Occlusion 1-13

Prevalence Rates: RVO, BRVO and CRVO 1-13

Treatable Patient Population 1-15

Market Trends 1-16

Market Engineering Measurements 1-16

Industry Challenges and Strategies 1-17

Off-Label Use of Avastin Significantly Suppresses Revenue Potential 1-18

Lengthy and Costly Clinical Trials Impede New Market Entrants 1-19

Developing Therapies to Treat Diseases of the Back-of-the-Eye is Complex 1-19

Established Treatment Alternatives Impede Success of New DME Therapies 1-19

Market Drivers 1-20

Worldwide Diabetes Epidemic Fuels Research into Vision-Compromising Comorbidities 1-20

Presence of Novel Biopharmaceuticals Boosts Market 1-21

Market Opportunity for Wet AMD Drugs Further Expanded by Penetration into other

Highly Lucrative Back-of-the-Eye Diseases 1-21

Advancements in Formulation Technology Opens New Routes to Revenue Generation 1-21

Aging Population to Significantly Increase Demand for Treatment 1-22

List of Figures

C h a p t e r 2

Market Introduction

2-1 Retinal Therapeutics Market:

Intermediate AMD and Advanced Dry AMD Prevalence Forecasts (U.S.), 2006-2016 1-6

2-2 Retinal Therapeutics Market:

Wet AMD Prevalence Forecast (U.S.), 2006-2016 1-7

2-3 Retinal Therapeutics Market:

Wet AMD Treated Patient Forecast (U.S.), 2006-2016 1-9

2-4 Retinal Therapeutics Market:

DR Prevalence Forecasts among All Diabetics and among Type I

Diabetics (U.S.), 2006-2016 1-11

2-5 Retinal Therapeutics Market:

Incidence and Treated Patient Forecasts for DME among Diagnosed

Diabetics (U.S.), 2006-2016 1-12

2-6 Retinal Therapeutics Market:

CRVO, BRVO, and Total RVO Prevalence Forecasts (U.S.), 2006-2016 1-14

2-7 Retinal Therapeutics Market:

BRVO, CRVO, and Total RVO Treatment-Eligible Patient Forecasts (U.S.), 2006-2016 1-15

2-8 Retinal Therapeutics Market:

Top Four Industry Challenges Ranked in Order of Impact (U.S.), 2011-2016 1-18

2-9 Retinal Therapeutics Market:

Market Drivers Ranked in Order of Impact (U.S.), 2011-2016 1-20

C h a p t e r 3

Treatment Overview and Product Pipeline

3-1 Retinal Therapeutics Market:

Wet AMD Pipeline Overview (U.S.), 2010 1-7

3-2 Retinal Therapeutics Market:

Dry AMD Pipeline Overview (U.S.), 2010 1-8

3-3 Retinal Therapeutics Market:

DR and DME Pipeline Overview (U.S.), 2010 1-9

3-4 Retinal Therapeutics Market:

RVO Pipeline Overview (U.S.), 2010 1-9

C h a p t e r 4

Market Analysis

4-1 Retinal Therapeutics Market:

Visudyne Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-2

4-2 Retinal Therapeutics Market:

Macugen Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-4

4-3 Retinal Therapeutics Market:

Product Market Share by Revenue - AMD Segment (U.S.), 2009 1-6

4-4 Retinal Therapeutics Market:

Product Market Share by Patients - AMD Segment (U.S.), 2009 1-7

4-5 Retinal Therapeutics Market:

VEGF Trap-EYE Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-10

4-6 Retinal Therapeutics Market:

Lucentis Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-12

4-7 Retinal Therapeutics Market:

Avastin Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-13

4-8 Retinal Therapeutics Market:

Total AMD Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-15

4-9 Retinal Therapeutics Market:

Product Market Share by Revenue - AMD Segment (U.S.), 2016 1-16

4-10 Retinal Therapeutics Market:

Product Market Share by Patients - AMD Segment (U.S.), 2016 1-17

4-11 Retinal Therapeutics Market:

Lucentis Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-21

4-12 Retinal Therapeutics Market:

Avastin Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-23

4-13 Retinal Therapeutics Market:

Iluvien Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-26

4-14 Retinal Therapeutics Market:

Ozurdex Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-28

4-15 Retinal Therapeutics Market:

Triamcinolone Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-30

4-16 Retinal Therapeutics Market:

Total DME Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-32

4-17 Retinal Therapeutics Market:

Product Market Share by Revenue - DME Segment (U.S.), 2016 1-33

4-18 Retinal Therapeutics Market:

Competitive Structure (U.S.), 2010 1-38

C h a p t e r 5

Appendix

5-1 Decision Support Database:

Total Population in Million (World), 2004-2014 1-1

5-2 Decision Support Database:

Population Aged 15 to 24 Years in Million (World), 2004-2014 1-4

5-3 Decision Support Database:

Population Aged 25 to 34 Years in Million (World), 2004-2014 1-6

5-4 Decision Support Database:

Population Aged 35 to 44 years in Million (World), 2004-2014 1-8

5-5 Decision Support Database:

Population Aged 45 to 54 Years in Million (World), 2004-2014 1-10

5-6 Decision Support Database:

Population Aged 55 to 64 Years in Million (World), 2004-2014 1-12

5-7 Decision Support Database:

Total Population 45 Plus in Million (World), 2004-2014 1-14

5-8 Decision Support Database:

Population 65 Plus in Million (World), 2004-2014 1-16

5-9 Decision Support Database:

AMD Population in '000 (World), 2002-2012 1-18

5-10 Decision Support Database:

New Cases of AMD in '000 (World), 2002-2012 1-20

5-11 Decision Support Database:

Prevalence of Diabetes in '000 (World), 2002-2012 1-22

5-12 Decision Support Database: New Cases of Diabetes in '000 (World), 2002-2012 1-25

List of Charts

C h a p t e r 2

Market Introduction

2.1 Retinal Therapeutics Market:

Market Segmentation by Disease (U.S.), 2009 1-2

2.2 Retinal Therapeutics Market:

Advanced Dry AMD and Intermediate AMD Prevalence Forecasts (U.S.), 2006-2016 1-6

2.3 Retinal Therapeutics Market:

Wet AMD Prevalence Forecast (U.S.), 2006-2016 1-8

2.4 Retinal Therapeutics Market:

Wet AMD Treated Patient Forecast (U.S.), 2006-2016 1-9

2.5 Retinal Therapeutics Market:

DR Prevalence among All Diabetics and among Type I Diabetics (U.S.), 2006-2016 1-11

2.6 Retinal Therapeutics Market:

Incidence and Treated Patient Forecasts for DME among Diagnosed Diabetics

(U.S.), 2006-2016 1-13

2.7 Retinal Therapeutics Market:

Prevalence Forecasts for BRVO, CRVO and Total RVO (U.S.) 2006-2016 1-14

2.8 Retinal Therapeutics Market:

Treatment-Eligible Patient Forecasts for BRVO, CRVO and Total RVO (U.S.), 2006-2016 1-16

2.9 Retinal Therapeutics Market:

Market Engineering Measurements (U.S.), 2009 1-17

C h a p t e r 4

Market Analysis

4.1 Retinal Therapeutics Market:

Visudyne Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-2

4.2 Retinal Therapeutics Market:

Macugen Revenue and Growth Rate Forecasts - AMD Segment (U.S.), 2006-2016 1-4

4.3 Retinal Therapeutics Market:

Product Market Share by Revenue - AMD Segment (U.S.), 2009 1-6

4.4 Retinal Therapeutics Market:

Product Market Share by Patients - AMD Segment (U.S.), 2009 1-7

4.5 Retinal Therapeutics Market: VEGF Trap-Eye Revenue and Growth Rate

Forecasts - AMD Segment (U.S.), 2006-2016 1-11

4.6 Retinal Therapeutics Market: Lucentis Revenue and Growth Rate

Forecasts - AMD Segment (U.S.), 2006-2016 1-12

4.7 Retinal Therapeutics Market: Avastin Revenue and Growth Rate

Forecasts - AMD Segment (U.S.), 2006-2016 1-14

4.8 Retinal Therapeutics Market: Total AMD Revenue and Growth Rate

Forecasts - AMD Segment (U.S.), 2006-2016 1-15

4.9 Retinal Therapeutics Market: Product Market Share by

Revenue - AMD Segment (U.S.), 2016 1-16

4.10 Retinal Therapeutics Market: Product Market Share by

Patients - AMD Segment (U.S.), 2016 1-17

4.11 Retinal Therapeutics Market: Lucentis Revenue and Growth Rate

Forecasts - DME Segment (U.S.), 2006-2016 1-22

4.12 Retinal Therapeutics Market: Avastin Revenue and Growth Rate

Forecasts - DME Segment (U.S.), 2006-2016 1-23

4.13 Retinal Therapeutics Market: Iluvien Revenue and Growth Rate

Forecasts - DME Segment (U.S.), 2006-2016 1-27

4.14 Retinal Therapeutics Market:

Ozurdex Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-29

4.15 Retinal Therapeutics Market:

Triamcinolone Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-31

4.16 Retinal Therapeutics Market:

Total DME Revenue and Growth Rate Forecasts - DME Segment (U.S.), 2006-2016 1-32

4.17 Retinal Therapeutics Market:

Product Market Share by Revenue - DME Segment (U.S.), 2016 1-33

2-1

To order this report:

Machine Tool and Equipment Industry: U.S. Retinal Therapeutics Market

Machine Tool and Equipment Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Global CRO Market: Quantitative Assessment
2. Reportlinker Adds The Outlook for Medical Devices in North East Asia
3. Reportlinker Adds Global Microbiology Testing Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
4. Reportlinker Adds Endovascular Surgical Interventions: Technology Market Penetration and Roadmapping
5. Reportlinker Adds Global Hemostasis Diagnostics Market: US, Europe, Japan--Emerging Opportunities and Business Expansion Strategies for Suppliers
6. Reportlinker Adds Global Nucleic Acid Testing Market--New Product Development Opportunities and Business Expansion Strategies For Instrument and Reagent Suppliers
7. Reportlinker Adds Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers
8. Reportlinker Adds Top Medical Devices and Imaging Technologies 2011
9. Reportlinker Adds US Wound Closure Devices - Market Trend Till 2016
10. Reportlinker Adds UK CT Systems - Market Trend Till 2016
11. Reportlinker Adds PE/VC Activity in Medical Devices - Number of PE/VC Investments in Small Sized Medical Devices Companies Has Increased in the Past Four Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
Breaking Medicine Technology:
(Date:7/26/2017)... San Jose, Calif (PRWEB) , ... July 26, 2017 , ... Six greater Bay Area ... save lives with “Make ‘em Bleed,” the most widely attended series of blood drives in ... 900 units of blood over the past 4 years -- enough to have helped to ...
(Date:7/26/2017)... ... ... It may be hard to imagine that the basic necessities that developed countries ... that many developed countries consider rare or eradicated, like measles, are still a rite ... an upcoming segment of "Success Files", actor Rob Lowe will introduce a new segment ...
(Date:7/26/2017)... ... July 27, 2017 , ... It's time to sign up for the ... great benefits," says Kathy Heshelow, founder of Sublime Naturals and author of numerous books on ... oil each month, mailed by the 5th. , Two items are included ...
(Date:7/26/2017)... ... ... “We are thrilled to be partnering with Six Month Smiles to work ... in real time,” said Keith English, LocalMed CEO. “Allowing patients the ability to schedule ... Month Smiles patients to their providers.” , Each month, over 25,000 patients research Six ...
(Date:7/26/2017)... ... 26, 2017 , ... Isodiol International Inc. (CSE: ISOL) (OTC: ... the development of pharmaceutical and consumer products, announces the operational numbers of its ... Iso International LLC recorded unaudited fiscal Q1 profits of $897,596 based on revenues ...
Breaking Medicine News(10 mins):